222556-21-0

Basic information

• Product Name: (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester
• Synonyms: (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester
• CAS NO: 222556-21-0
• Molecular Weight: 344.408
• Mol File: 222556-21-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester(222556-21-0)
• EPA Substance Registry System: (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester(222556-21-0)

Safety Data

• Hazardous Substances Data: 222556-21-0(Hazardous Substances Data)

Usage

General Description

(S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester is a compound with a complex chemical structure that consists of a tetrahydropyridazine ring with three carboxylic acid groups, as well as two tert-butyl and one methyl ester groups attached to the ring. (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester is likely a derivative or analog of a biologically active molecule with potential pharmaceutical or research applications. The specific properties and potential uses of this compound would require further investigation and analysis.

Upstream product

• 67-56-1 methanol 
• 156699-38-6 (4S)-3-<(3S)-N,N'-bis(t-butoxycarbonyl)hexahydropyridazine-3-carboxy>-4-phenylmethyl-2-oxazolidinone 
• 186581-53-3 diazomethane 
• 1219380-72-9 N,N'-di-tert-butoxycarbonylpiperazic acid 
• 156699-39-7 (3S)-N,N'-bis-(t-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 1219114-45-0 di-tert-butyl 3-[(S)-4-benzyl-2-oxo-1,3-oxazolidine-3-carbonyl]hexahydropyridazine-1,2-dicarboxylate 

Downstream Products

• 321983-71-5 hept-6-en-1-oyl-L-valine-L-phenylalanine-hexahydropyridazine-3S-carboxylic acid hex-5-enyl ester 
• 321983-72-6 (E)-(3S,6S,21S)-3-benzyl-6-isopropyl-19-oxa-1,4,7,25-tetraaza-bicyclo[19.3.1]-pentacos-13-ene-2,5,8,20-tetraone 
• 247186-18-1 hept-6-en-1-oyl-L-valine-L-phenylalanine-hexahydropyridazine-3S-carboxylic acid hexa-3,5-dienyl ester 
• 247186-17-0 hept-6-en-oyl-L-valine-L-phenylalanine-hexahydropyridazine-3S-carboxylic acid methyl ester 
• 247186-16-9 (tert-butoxycarbonyl)-L-valine-L-phenylalanine-hexahydropyridazine-3S-carboxylic asid methyl ester 
• 247186-15-8 (tert-butoxycarbonyl)-L-phenylalanine-hexahydropyridazine-3S-carboxylic acid methyl ester 
• 222556-14-1 (S)-1-[(S)-3-(3-Benzyloxy-phenyl)-2-((S)-2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-propionyl]-hexahydro-pyridazine-3-carboxylic acid methyl ester 
• 138323-07-6 methyl (S)-hexahydropyridazine-3-carboxylate 

Relevant articles and documents

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Synthesis of the tripeptide domain of sanglifehrins using asymmetric phase-transfer catalysis

The tripeptide (S)-valinyl-(S)-m-hydroxyphenylalanyl-(3S)-piperazate common to immunosuppressant sanglifehrins was synthesized from the constituent amino acid residues in nine steps and 42% overall yield. A key construction was the installation of (S) absolute configuration in m-hydroxyphenylalanine using asymmetric phase-transfer catalysis in the presence of N-(1-naphthyl) cinchonidinium bromide. Cbz-protected (S)-valine was first coupled to the amino group of (S)-m-triisopropylsilyloxyphenylalanine tert-butyl ester, and the resulting dipeptide after ester cleavage was linked to (3S)-methyl piperazate.

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula I and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.